US equities
|
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SNDK
$1,238.03
▲+0.00%
SPCX
$147.49
▲+0.00%
NBIS
$158.74
▲+0.00%
NVDA
$210.96
▲+0.00%
AAPL
$347.73
▲+0.00%
NU
$15.16
▲+0.00%
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SNDK
$1,238.03
▲+0.00%
SPCX
$147.49
▲+0.00%
NBIS
$158.74
▲+0.00%
NVDA
$210.96
▲+0.00%
AAPL
$347.73
▲+0.00%
NU
$15.16
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
88.11
+0.00 (+0.01%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BioNTech SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
Today 5:00 EDT
From
BioNTech SE
Via
GlobeNewswire
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
October 25, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
October 22, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
October 20, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
October 19, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
October 13, 2026
From
BioNTech SE
Via
GlobeNewswire
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END
Via
FinancialNewsMedia
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers
From
MarketNewsUpdates.com
Via
GlobeNewswire
BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
September 14, 2026
From
BioNTech SE
Via
GlobeNewswire
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
August 27, 2026
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
August 27, 2026
From
BioNTech SE
Via
GlobeNewswire
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology
From
MarketNewsUpdates.com
Via
GlobeNewswire
BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
August 20, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
August 04, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
August 03, 2026
From
BioNTech SE
Via
GlobeNewswire
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
July 29, 2026
From
Pfizer Inc.
Via
Business Wire
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
July 29, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
July 21, 2026
From
BioNTech SE
Via
GlobeNewswire
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
May 30, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
May 22, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
May 15, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces New ADS Repurchase Program
May 07, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
May 05, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
April 21, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
April 11, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
March 24, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
March 10, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
March 10, 2026
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
February 24, 2026
From
BioNTech SE
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
